Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Sopharma AD-Sofia's 3-Year RORE % for the quarter that ended in Dec. 2023 was 0.00%.
The industry rank for Sopharma AD-Sofia's 3-Year RORE % or its related term are showing as below:
FRA:3JR's 3-Year RORE % is not ranked *
in the Medical Distribution industry.
Industry Median: -0.975 * Ranked among companies with meaningful 3-Year RORE % only.
Sopharma AD-Sofia 3-Year RORE % Historical Data
The historical data trend for Sopharma AD-Sofia's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sopharma AD-Sofia's 3-Year RORE %
For the Medical Distribution subindustry, Sopharma AD-Sofia's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma AD-Sofia's 3-Year RORE % Distribution in the Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Sopharma AD-Sofia's 3-Year RORE % falls into.
Sopharma AD-Sofia 3-Year RORE % Calculation
Sopharma AD-Sofia's 3-Year RORE % for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2023 and 3-year before.
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Sopharma AD-Sofia 3-Year RORE % Related Terms
Thank you for viewing the detailed overview of Sopharma AD-Sofia's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are organized based on the production of finished products which include Tablet dosage forms, Ampoule dosage forms, Medical products, Other forms, and Other revenue. Geographically company operates in Bulgaria and internationally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:3JR has been successfully added to your 